RemeGen (9995) Announces RMB400 Million Principal-Guaranteed Wealth Management Product Purchase

Bulletin Express

Nov 03

RemeGen Co., Ltd. (Stock Code: 9995) approved a resolution on March 27, 2025, authorizing the use of up to RMB500 million of idle self-owned funds for principal-guaranteed bank wealth management products. According to the latest announcement, RemeGen formalized an agreement on November 3, 2025, with Shanghai Pudong Development Bank (SPDB) Yantai Branch to purchase a product valued at RMB400 million.

Under the terms of this 25-day principal-guaranteed product, the expected annualized yield ranges among 0.7%, 1.65%, or 1.85%, and its linked target focuses on the EUR-USD exchange rate. RemeGen previously signed a separate RMB100 million principal-guaranteed agreement with the same bank on October 15, 2025. Due to aggregation rules, the current purchase will count together with the earlier agreement and constitutes a discloseable transaction under Chapter 14 of the Listing Rules, triggered by exceeding the 5% threshold while remaining under 25%.

RemeGen highlighted that this use of idle self-owned funds aims to secure reasonable capital gains and maintain low risk. The board of directors considers these terms fair and in the interests of the company and its shareholders. RemeGen is a biopharmaceutical company specializing in innovative treatments for autoimmune, oncology, and ophthalmic diseases in China and internationally.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1195756697"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1195756697\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1195756697?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-03 23:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1195756697","market":"hk","top_or_hot":-1,"title":"RemeGen (9995) Announces RMB400 Million Principal-Guaranteed Wealth Management Product Purchase","media":"Bulletin Express","content":"<p>RemeGen Co., Ltd. (Stock Code: 9995) approved a resolution on March 27, 2025, authorizing the use of up to RMB500 million of idle self-owned funds for principal-guaranteed bank wealth management products. According to the latest announcement, RemeGen formalized an agreement on November 3, 2025, with Shanghai Pudong Development Bank (SPDB) Yantai Branch to purchase a product valued at RMB400 million.</p>\n<p>Under the terms of this 25-day principal-guaranteed product, the expected annualized yield ranges among 0.7%, 1.65%, or 1.85%, and its linked target focuses on the EUR-USD exchange rate. RemeGen previously signed a separate RMB100 million principal-guaranteed agreement with the same bank on October 15, 2025. Due to aggregation rules, the current purchase will count together with the earlier agreement and constitutes a discloseable transaction under Chapter 14 of the Listing Rules, triggered by exceeding the 5% threshold while remaining under 25%.</p>\n<p>RemeGen highlighted that this use of idle self-owned funds aims to secure reasonable capital gains and maintain low risk. The board of directors considers these terms fair and in the interests of the company and its shareholders. RemeGen is a biopharmaceutical company specializing in innovative treatments for autoimmune, oncology, and ophthalmic diseases in China and internationally.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RemeGen (9995) Announces RMB400 Million Principal-Guaranteed Wealth Management Product Purchase</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRemeGen (9995) Announces RMB400 Million Principal-Guaranteed Wealth Management Product Purchase\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-11-03 23:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>RemeGen Co., Ltd. (Stock Code: 9995) approved a resolution on March 27, 2025, authorizing the use of up to RMB500 million of idle self-owned funds for principal-guaranteed bank wealth management products. According to the latest announcement, RemeGen formalized an agreement on November 3, 2025, with Shanghai Pudong Development Bank (SPDB) Yantai Branch to purchase a product valued at RMB400 million.</p>\n<p>Under the terms of this 25-day principal-guaranteed product, the expected annualized yield ranges among 0.7%, 1.65%, or 1.85%, and its linked target focuses on the EUR-USD exchange rate. RemeGen previously signed a separate RMB100 million principal-guaranteed agreement with the same bank on October 15, 2025. Due to aggregation rules, the current purchase will count together with the earlier agreement and constitutes a discloseable transaction under Chapter 14 of the Listing Rules, triggered by exceeding the 5% threshold while remaining under 25%.</p>\n<p>RemeGen highlighted that this use of idle self-owned funds aims to secure reasonable capital gains and maintain low risk. The board of directors considers these terms fair and in the interests of the company and its shareholders. RemeGen is a biopharmaceutical company specializing in innovative treatments for autoimmune, oncology, and ophthalmic diseases in China and internationally.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1195756697","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1195756697","pubTimestamp":1762185352,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"RemeGen Co., Ltd. (Stock Code: 9995) approved a resolution on March 27, 2025, authorizing the use of up to RMB500 million of idle self-owned funds for principal-guaranteed bank wealth management...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"瑞美健(9995)宣布购买人民币4亿元保本理财产品","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"RemeGen Co., Ltd. (Stock Code: 9995) approved a resolution on March 27, 2025, authorizing the use of up to RMB500 million of idle self-owned funds for principal-guaranteed bank wealth management products. According to the latest announcement, RemeGen formalized an agreement on November 3, 2025, with Shanghai Pudong Development Bank (SPDB) Yantai Branch to purchase a product valued at RMB400 million.\nUnder the terms of this 25-day principal-guaranteed product, the expected annualized yield ranges among 0.7%, 1.65%, or 1.85%, and its linked target focuses on the EUR-USD exchange rate. RemeGen previously signed a separate RMB100 million principal-guaranteed agreement with the same bank on October 15, 2025. Due to aggregation rules, the current purchase will count together with the earlier agreement and constitutes a discloseable transaction under Chapter 14 of the Listing Rules, triggered by exceeding the 5% threshold while remaining under 25%.\nRemeGen highlighted that this use of idle self-owned funds aims to secure reasonable capital gains and maintain low risk. The board of directors considers these terms fair and in the interests of the company and its shareholders. RemeGen is a biopharmaceutical company specializing in innovative treatments for autoimmune, oncology, and ophthalmic diseases in China and internationally.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}